Navigation Links
Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
Date:4/17/2008

a further increases our interest in exploring the combination of ANA598 with interferon and ribavirin as well as with other experimental direct antivirals."

About ANA598

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5b inhibitor, cellular activity in the hepatitis C replicon assay, oral bioavailability and early indicators of safety and tolerability. Anadys has recently completed IND enabling activities for ANA598 and pending allowance by the Food and Drug Administration, intends to initiate clinical studies of ANA598 in healthy volunteers in the second quarter of 2008. Following the healthy volunteer study, in the third quarter of 2008 Anadys plans to initiate a short-term Phase Ib study in patients infected with chronic HCV infection.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5B polymerase for the treatment of chronic hepatitis C and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598, including future clinical trials and the belief that ANA598 has the broad potential utility to be used in combination with other anti-HCV agents, regardless of class, as well as the belief that ANA598 will be an active antiviral in HCV infected patients. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materiall
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Quebec , Sept. 30, 2014 Valeant ... TSX: VRX) today announced that the company,s ... Letter from the U.S. Food and Drug Administration (FDA) ... Company,s records with regards to Sculptra Aesthetic injectable, which ... Warning Letter pertains to the management of Valeant,s contract manufacturers ...
(Date:9/30/2014)... , Sept. 30, 2014  HealthLoop® released an ... with HealthKit in iOS 8 and allows people to ... The app harnesses native iOS technologies to enhance the ... a robust connection with their doctors between visits. ... and the data they collect is exciting," says HealthLoop ...
(Date:9/30/2014)... MOUNTAIN VIEW, Calif. , Sept. 30, 2014 ... oncology tissue diagnostics market, Frost & Sullivan recognizes ... the Roche Group, with the 2014 North American ... Adherence to strict quality practices along with a ... made Ventana a global leader in tissue-based cancer ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2HealthLoop Integrates with Apple's HealthKit Enabling Patients to Share Health Data with Their Doctors Right from their iPhone 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 2Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 3Frost & Sullivan applauds the diversity of Ventana products and services for the cancer diagnostics market 4
... and Drug Administration today issued new guidance that advises ... to administer influenza vaccinations. Based on this advice, The ... use of such clinical devices at all pharmacies and ... family of pharmacies and The Little Clinic locations will ...
... 21, 2011 Boca Pharmacal, Inc., today announced that it ... Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and ... and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, ... in the treatment of peptic ulcers. "We,re up ...
Cached Medicine Technology:Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets 2
(Date:9/30/2014)... NV (PRWEB) September 30, 2014 Elevate ... helping people perform better in and out of the gym ... memory has caught the attention of Shane Michaels, prompting an ... grind, fatigue is the reason most people simply just don’t ... that means staying focused at work, getting the motivation to ...
(Date:9/30/2014)... 2014 VisitandCare.com reports that ... gone up more than 79 percent in 2014, marking ... also reported total revenue tripled for its entirety of ... professional strategy has allowed them to partner with ... patient comfort and privacy — with state-of-the-art surgical atmospheres ...
(Date:9/30/2014)... 2014 Hospice & Palliative Care ... Celebration” gala, honoring three outstanding individuals for their ... to provide extraordinary and dignified comfort, care and ... or life-limiting illness. , The event was held ... and recognized William (Bill) J. McGuinness, Director of ...
(Date:9/30/2014)... September 30, 2014 Regenerative Medicine Solutions ... new clinics in Nashville, Tennessee. RMS welcomes the launch ... and the expansion of a new treatment center for ... the Sleep Apnea Institute to Nashville, the hope is ... sleep apnea: both diagnosed and undiagnosed. With Nashville being ...
(Date:9/30/2014)... Dr. Karl R.O.S. Johnson, DC, has ... of care that is dramatically improving the health and ... Neurology & Nutrition—applies a proprietary, multi-dimensional approach that goes ... sources of inflammation, neurology of the joint and neurology ... the brain to the spine, to the legs, knees ...
Breaking Medicine News(10 mins):Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... that the U.S. Food and Drug Administration has approved ... prostate cancer patients, marks the beginning of an era ... the standard therapeutic arsenal against cancer, say Dana-Farber Cancer ... effectiveness in patients. The study the results ...
... ... Illness (NAMI), NAMIWalks help raise funds for local programs. , ... (PRWEB) -- May is Mental Health Month. This weekend, Saturday ... NAMIWalks to raise public awareness about facts concerning mental illness and the ...
... from all drugs used to prevent organ rejection, researchers ... type of drug treatment used to prevent organ rejection ... new study finds. , Kidney transplant patients are at ... use of immunosuppressive drugs to prevent organ rejection. In ...
... ... gastroenterologists from around the world to launch the first international “World IBD Day” dedicated ... conference (May 2 -5) in New Orleans. , ... New York, New York (Vocus) April 29, 2010 -- ...
... of ill people triggered greater response than pictures of gun-wielding ... a sick person may give your immune system a boost, ... sets of slides on two different days. The first set ... either a slideshow that showed photos of people with pox, ...
... This release is available in French . ... in Immunology and Cancer (IRIC) of the Universit de Montral ... ribonucleic acid (RNA) engineering laboratory in Canada. Led by Franois ... of Gerardo Ferbeyre, biochemistry researcher with the Faculty of Medicine ...
Cached Medicine News:Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 2Health News:Dana-Farber/Provenge: Approval of prostate cancer immunotherapy-new era of cancer treatments 3Health News:NAMIWalks Kicks-off “Mental Health Month”; Fun Events that Support Serious Work 2Health News:Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 2Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 3Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 4Health News:First Annual Observance of World IBD Day Draws Awareness to Growing Global Incidence of Inflammatory Bowel Disease 5Health News:Cells programmed to cure and even prevent cancer 2
... Streptavidin magnetic beads are designed ... biotinylated molecules such as DNA, ... cell lysates or hybridization reactions. ... dispersed, it can also be ...
... Streptavidin magnetic beads are ... covalently coupled to a ... substrates can be useful ... experiments including mRNA isolation ...
... For the detection P.falciparum ... and pan specific pLDH, for differentiation ... other malarial species viz P.vivax ... P. malariae and for the ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
Medicine Products: